A new set of therapeutics for inflammatory and vascular disorders is being developed in Cleveland – based on research from a trio of lauded cardiovascular researchers.
Sujana Biotech just raised $800,000 of a potential $5 million round, according to a regulatory filing.
According to BioMotiv, the scientific backing for the new therapeutics come from Daniel Simon, chief of cardiovascular medicine at the University Hospitals Harrington Heart & Vascular Institute; Edward Plow, a department chair in molecular cardiology at Cleveland Clinic; and Yunmei Wang, an assistant professor of cardiology at Case Western Reserve University.
BioMotiv is the for-profit affiliate of University Hospitals’ Harrington Project, a $250 million initiative created to bridge the “valley of death” in drug development by accelerating the development and commercialization of medical breakthroughs from research centers.
Calls to Sujana Biotech and BioMotiv have not yet been returned.
